United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

boehringer ingelheim ltd - ipratropium bromide; salbutamol sulfate - nebuliser liquid - 200microgram/1ml ; 1mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - ipratropium bromide monohydrate salbutamol sulfate - nebuliser solution - 0.5/2.5 base milligrams

Ireland - English - HPRA (Health Products Regulatory Authority)

b & s healthcare - ipratropium bromide monohydrate salbutamol sulfate - nebuliser solution - 0.5/2.5 base milligrams

Canada - English - Health Canada

teva canada limited - ipratropium bromide; salbutamol (salbutamol sulfate) - solution - 0.5mg; 2.5mg - ipratropium bromide 0.5mg; salbutamol (salbutamol sulfate) 2.5mg - antimuscarinics antispasmodics

Canada - English - Health Canada

teva canada limited - salbutamol (salbutamol sulfate); ipratropium bromide (ipratropium bromide monohydrate) - solution - 2.5mg; 0.5mg - salbutamol (salbutamol sulfate) 2.5mg; ipratropium bromide (ipratropium bromide monohydrate) 0.5mg - antimuscarinics antispasmodics

Canada - English - Health Canada

juno pharmaceuticals corp. - ipratropium bromide (ipratropium bromide monohydrate); salbutamol (salbutamol sulfate) - solution - 0.5mg; 2.5mg - ipratropium bromide (ipratropium bromide monohydrate) 0.5mg; salbutamol (salbutamol sulfate) 2.5mg - antimuscarinics antispasmodics

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul), albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e) - ipratropium bromide anhydrous 20 ug - combivent respimat is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (copd) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. combivent respimat is contraindicated in the following conditions [see warnings and precautions (5.6) ]: - hypersensitivity to any of the ingredients in combivent respimat - hypersensitivity to atropine or any of its derivatives risk summary there are no randomized clinical studies of combivent respimat, or its individual components, ipratropium bromide and albuterol sulfate, in pregnant women. ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . published literature, including cohort studies, case control studies and case series, over s

Canada - English - Health Canada

apotex inc - ipratropium bromide (ipratropium bromide monohydrate); salbutamol (salbutamol sulfate) - solution - 0.5mg; 2.5mg - ipratropium bromide (ipratropium bromide monohydrate) 0.5mg; salbutamol (salbutamol sulfate) 2.5mg - antimuscarinics antispasmodics

Canada - English - Health Canada

aa pharma inc - ipratropium bromide - solution - 250mcg - ipratropium bromide 250mcg - antimuscarinics antispasmodics

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - ipratropium bromide salbutamol sulfate - pressurised inhalation suspension - 20/100mcg/ mcg/dose